Literature DB >> 9616364

Immunoglobulin VH gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumours with clinical features of human disease.

D Zhu1, C van Arkel, C A King, S V Meirvenne, C de Greef, K Thielemans, J Radl, F K Stevenson.   

Abstract

The 5T series of multiple myelomas (MM) and Waldenstrsöm's macroglobulinaemia-like lymphomas (WM), which developed spontaneously in ageing mice of the C57BL/KaLwRij strain, shows clinical and biological features that closely resemble their corresponding human diseases. In order to compare the patterns of somatic mutation in VH genes of mouse tumours with those of human counterparts, we have determined and analysed sequences of immunoglobulin VH genes in five cases of murine MM, two of WM and one of biclonal benign monoclonal gammopathy (BMG). Four of five MM and 2/2 WM cases used VH genes of the large J558 family; one MM used a gene of the VGAM3.8 family, and both clones of the BMG used genes of the 36-60 family. N-region insertions were observed in all cases, but D-segment genes were only identified in 6/9 cases, which were all from the D-SP family and translated in reading frame 3. Compared with human MM, in which the VH genes have been found to be consistently hypermutated (mean% +/- SD = 8.8 +/- 3.2), the degree of somatic mutation in the murine tumours was significantly lower (mean% +/- SD = 2.9 +/- 2.3). There was no significant evidence of clustering of replacement mutations in complementarity determining regions (CDR), a feature considered to be characteristic of antigen-selected sequences. However, one clone of the biclonal BMG case showed intraclonal variation, a feature described in some cases of human BMG. These results indicate that murine VH genes in mature tumours differ from human counterparts in the level and distribution of somatic mutations, but support the concept that BMG may be distinct from MM.

Entities:  

Mesh:

Year:  1998        PMID: 9616364      PMCID: PMC1364174          DOI: 10.1046/j.1365-2567.1998.00428.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Frequency of clonal dominance in the specific antibody response to DNP-HSA in CBA and C57BL mice reflects their susceptibility to age-associated development of monoclonal gammopathies.

Authors:  C van Arkel; F J Nooij; A J van der Sluijs-Gelling; J Radl
Journal:  Clin Immunol Immunopathol       Date:  1997-06

2.  Animal model of human disease. Multiple myeloma.

Authors:  J Radl; J W Croese; C Zurcher; M H Van den Enden-Vieveen; A M de Leeuw
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

3.  Tenfold increased incidence of spontaneous multiple myeloma in long-term immunosuppressed aging C57BL/KaLwRij mice.

Authors:  J Radl; C Van Arkel; C M Hopstaken; H HogenEsch
Journal:  Clin Immunol Immunopathol       Date:  1996-05

4.  Analysis of immunoglobulin heavy chain V-region genes belonging to the V NP-gene family.

Authors:  T Blankenstein; G Zoebelein; U Krawinkel
Journal:  Nucleic Acids Res       Date:  1984-09-11       Impact factor: 16.971

5.  Simultaneous expression of immunoglobulin mu and delta heavy chains by a cloned B-cell lymphoma: a single copy of the VH gene is shared by two adjacent CH genes.

Authors:  M R Knapp; C P Liu; N Newell; R B Ward; P W Tucker; S Strober; F Blattner
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

6.  Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A.

Authors:  L K Sun; P Curtis; E Rakowicz-Szulczynska; J Ghrayeb; N Chang; S L Morrison; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

7.  Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells.

Authors:  S S Sahota; R Leo; T J Hamblin; F K Stevenson
Journal:  Blood       Date:  1997-01-01       Impact factor: 22.113

8.  Molecular and kinetic analysis of an epitope-specific shift in the B cell memory response to a multideterminant antigen.

Authors:  J L Press; C A Giorgetti
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

9.  Cytogenetic findings in mouse multiple myeloma and Waldenström's macroglobulinemia.

Authors:  T W van den Akker; J Radl; E Franken-Postma; A Hagemeijer
Journal:  Cancer Genet Cytogenet       Date:  1996-02

10.  Allelic immunoglobulin VH genes in two mouse strains: possible germline gene recombination.

Authors:  J B Cohen; D Givol
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  5 in total

1.  Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.

Authors:  Pramod S Gowda; Benjamin J Wildman; Timothy N Trotter; Xiaoxuan Xu; Xiaoxiao Hao; Mohammad Q Hassan; Yang Yang
Journal:  Mol Cancer Res       Date:  2018-03-28       Impact factor: 5.852

2.  Myeloma cell-derived Runx2 promotes myeloma progression in bone.

Authors:  Timothy N Trotter; Mei Li; Qianying Pan; Deniz Peker; Patrick D Rowan; Juan Li; Fenghuang Zhan; Larry J Suva; Amjad Javed; Yang Yang
Journal:  Blood       Date:  2015-04-10       Impact factor: 22.113

3.  Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.

Authors:  Natalia Savelyeva; Catherine A King; Ellen S Vitetta; Freda K Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-21       Impact factor: 11.205

4.  Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging.

Authors:  Babatunde O Oyajobi; Steve Muñoz; Rami Kakonen; Paul J Williams; Anjana Gupta; Christi L Wideman; Beryl Story; Barry Grubbs; Allison Armstrong; William C Dougall; I Ross Garrett; Gregory R Mundy
Journal:  Mol Cancer Ther       Date:  2007-05-31       Impact factor: 6.261

5.  Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.

Authors:  K Vanderkerken; C De Greef; K Asosingh; B Arteta; M De Veerman; I Vande Broek; I Van Riet; M Kobayashi; B Smedsrod; B Van Camp
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.